Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Shouse

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
American Journal of Clinical Pathology|September 18, 2024
Epstein-Barr virus-positive, primary cutaneous marginal zone lymphoma, with transformation: Case report and review of the literatureLori Soma, Liliana Crisan, Jack Reid, et al.
Bone Marrow Transplantation|July 4, 2026
CHIME: a novel HLA eplet model associates with non-relapse mortality in haploidentical hematopoietic cell transplant with post-transplant cyclophosphamideMichael Carter, Sunmin Park, Michiko Taniguchi, et al.
Future Oncology (London, England)|September 4, 2024
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignanciesRonnie Shapira-Frommer, Jiaxin Niu, Ruth Perets, et al.
American Journal of Clinical Pathology|June 29, 2026
CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myelomaV Rakesh Sethapati, Vu Ngo, Alexey Danilov, et al.
Haematologica|November 27, 2025
Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphomaAdam J Olszewski, Thomas A Ollila, Dai Chihara, et al.
Molecular Cancer Therapeutics|July 7, 2023
T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic LeukemiaVi Lam, Carly Roleder, Tingting Liu, et al.
Transplantation and Cellular Therapy|May 20, 2026
High incidence of cytomegalovirus infection in patients receiving standard of care CD19- or BCMA-targeted CAR T-cell therapies for hematologic malignanciesTamer Othman, John H Baird, Yan Wang, et al.
Cell Death & Disease|March 17, 2022
Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphomaElana Thieme, Tingting Liu, Nur Bruss, et al.
Transplantation and Cellular Therapy|June 13, 2024
Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) TherapyScott R Goldsmith, Geoffrey Shouse, F Lennie Wong, et al.
Experimental Hematology & Oncology|May 14, 2025
Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite studyNarendranath Epperla, Geoffrey Shouse, Natalie S Grover, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
American Journal of Clinical Pathology|September 18, 2024
Epstein-Barr virus-positive, primary cutaneous marginal zone lymphoma, with transformation: Case report and review of the literatureLori Soma, Liliana Crisan, Jack Reid, et al.
Bone Marrow Transplantation|July 4, 2026
CHIME: a novel HLA eplet model associates with non-relapse mortality in haploidentical hematopoietic cell transplant with post-transplant cyclophosphamideMichael Carter, Sunmin Park, Michiko Taniguchi, et al.
Future Oncology (London, England)|September 4, 2024
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignanciesRonnie Shapira-Frommer, Jiaxin Niu, Ruth Perets, et al.
American Journal of Clinical Pathology|June 29, 2026
CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myelomaV Rakesh Sethapati, Vu Ngo, Alexey Danilov, et al.
Haematologica|November 27, 2025
Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphomaAdam J Olszewski, Thomas A Ollila, Dai Chihara, et al.
Molecular Cancer Therapeutics|July 7, 2023
T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic LeukemiaVi Lam, Carly Roleder, Tingting Liu, et al.
Transplantation and Cellular Therapy|May 20, 2026
High incidence of cytomegalovirus infection in patients receiving standard of care CD19- or BCMA-targeted CAR T-cell therapies for hematologic malignanciesTamer Othman, John H Baird, Yan Wang, et al.
Cell Death & Disease|March 17, 2022
Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphomaElana Thieme, Tingting Liu, Nur Bruss, et al.
Transplantation and Cellular Therapy|June 13, 2024
Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) TherapyScott R Goldsmith, Geoffrey Shouse, F Lennie Wong, et al.
Experimental Hematology & Oncology|May 14, 2025
Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite studyNarendranath Epperla, Geoffrey Shouse, Natalie S Grover, et al.
Pageof 6